Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mesenchymal stem cells (Stem Med)
- Development stage
- Unknown
- Lead developer
- Stem Med
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous bone marrow-derived mesenchymal stem cell (MSC) therapy is a cell-based biologic being developed by Stem Med Pte. Ltd. for the treatment of liver cirrhosis, particularly for patients with Child-Pugh class B or C. The treatment process involves harvesting 100-200ml of bone marrow from the patient, isolating and culturing the mesenchymal stem cells ex vivo, and then reinfusing the expanded cells back into the patient. The therapeutic effect is driven by the MSCs' multi-pronged mechanism, which includes differentiating into functional hepatocytes, secreting paracrine factors to stimulate endogenous liver cell regeneration, reducing hepatic fibrosis, and exerting immunomodulatory effects to stabilize the liver microenvironment. This therapy aims to improve liver function and extend survival as a potential alternative to liver transplantation for patients with decompensated cirrhosis.
- Other names
- Autologous BM MSCAutologous bone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on autologous bone marrow mesenchymal stem cells (Stem Med).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mesenchymal stem cells (Stem Med).